LAT1 is expressed specifically in tumors and can be referred to as a “tumor cell type transporter”, whereas LAT2 is mainly expressed in normal cells and can be referred to as “a normal cell type transporter.” Since pan-LAT inhibitors also inhibit LAT2 simultaneously, their toxicity to normal cells has been reported [9]. Here, SLC7A5 is linked to neoplasm.